Travel Stocks Jump on Hope Pfizer Pill Signals New Reopening
(Bloomberg) -- Travel and leisure stocks, hurt for months by fears of the delta variant, staged a comeback on Friday after Pfizer Inc. announced its pill reduced Covid-19 hospitalizations and deaths substantially.
Investors bet that the drug, the second promising candidate for treating Covid-19 patients, will help tame the pandemic and speed up the comeback of travel. Airline stocks jumped 7% in their best day since November 2020. Shares of cruise lines advanced as well, while some of the biggest tech companies, many of which have benefited from consumers spending more time at home, fell.
“This could be the beginning of the second leg of the reopening trade, where international and business travel accelerates,” said Andrew Ross, a managing member of Confluence Global Capital.
Norwegian Cruise Line Holdings Ltd. rose 7.8%, Carnival Corp. climbed 8.3%, while Royal Caribbean Cruises Ltd. added 9%. While shares of Pfizer soared 10.9%, vaccine competitor Moderna Inc. slumped 16.6%. Among tech companies, Netflix Inc. shares fell 3.4%, and Microsoft edged 0.1% lower.
Earlier: JPMorgan's Kolanovic Says Time to Cut Tech in Reopening Revival
Last month, Merck & Co. and partner Ridgeback Biotherapeutics LP submitted their experimental pill to regulators after a study showed it slashed the risk of getting seriously ill or dying by half in patients with mild-to-moderate Covid-19.
Airlines have recently signaled that customers may be growing more willing to travel. Delta Air Lines said on Thursday its international bookings surged 450% in the six weeks since the U.S. announced it's reopening to fully vaccinated travelers from abroad. The news has helped propel a 13% rally in the stock this week, the biggest since November 2020.
©2021 Bloomberg L.P.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.